Aequus Pharmaceuticals Inc. (AQS.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.08 Million CAD | -35.78% |
| 2022 | 1.69 Million CAD | -61.1% |
| 2021 | 4.34 Million CAD | 38.71% |
| 2020 | 3.13 Million CAD | 87.41% |
| 2019 | 1.67 Million CAD | -16.22% |
| 2018 | 1.99 Million CAD | -25.28% |
| 2017 | 2.67 Million CAD | 32.92% |
| 2016 | 2.01 Million CAD | -17.27% |
| 2015 | 2.42 Million CAD | -33.72% |
| 2014 | 3.66 Million CAD | 986.74% |
| 2013 | 337.33 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1 Million CAD | -7.6% |
| 2024 Q1 | 1.09 Million CAD | 0.56% |
| 2023 Q3 | 1.17 Million CAD | 32.4% |
| 2023 FY | 1.08 Million CAD | -35.78% |
| 2023 Q4 | 1.08 Million CAD | -7.3% |
| 2023 Q1 | 962.71 Thousand CAD | -43.08% |
| 2023 Q2 | 885.04 Thousand CAD | -8.07% |
| 2022 Q1 | 3.54 Million CAD | -18.45% |
| 2022 Q3 | 2.67 Million CAD | 3.29% |
| 2022 Q2 | 2.58 Million CAD | -27.02% |
| 2022 FY | 1.69 Million CAD | -61.1% |
| 2022 Q4 | 1.69 Million CAD | -36.71% |
| 2021 Q1 | 4.48 Million CAD | 42.95% |
| 2021 FY | 4.34 Million CAD | 38.71% |
| 2021 Q4 | 4.34 Million CAD | -5.65% |
| 2021 Q3 | 4.6 Million CAD | -4.68% |
| 2021 Q2 | 4.83 Million CAD | 7.9% |
| 2020 Q2 | 1.33 Million CAD | -9.33% |
| 2020 Q3 | 3.7 Million CAD | 176.27% |
| 2020 Q4 | 3.13 Million CAD | -15.32% |
| 2020 FY | 3.13 Million CAD | 87.41% |
| 2020 Q1 | 1.47 Million CAD | -11.65% |
| 2019 Q3 | 2.62 Million CAD | -16.55% |
| 2019 Q1 | 1.95 Million CAD | -1.87% |
| 2019 Q2 | 3.14 Million CAD | 60.42% |
| 2019 Q4 | 1.67 Million CAD | -36.23% |
| 2019 FY | 1.67 Million CAD | -16.22% |
| 2018 Q4 | 1.99 Million CAD | -28.29% |
| 2018 Q2 | 1.86 Million CAD | -17.26% |
| 2018 Q1 | 2.25 Million CAD | -15.73% |
| 2018 FY | 1.99 Million CAD | -25.28% |
| 2018 Q3 | 2.78 Million CAD | 49.45% |
| 2017 Q4 | 2.67 Million CAD | -20.29% |
| 2017 Q1 | 5.54 Million CAD | 175.64% |
| 2017 FY | 2.67 Million CAD | 32.92% |
| 2017 Q2 | 4.54 Million CAD | -17.93% |
| 2017 Q3 | 3.35 Million CAD | -26.29% |
| 2016 Q1 | 2.57 Million CAD | 5.92% |
| 2016 Q2 | 1.88 Million CAD | -26.58% |
| 2016 FY | 2.01 Million CAD | -17.27% |
| 2016 Q4 | 2.01 Million CAD | -32.75% |
| 2016 Q3 | 2.98 Million CAD | 58.17% |
| 2015 Q1 | 2.44 Million CAD | -33.41% |
| 2015 Q3 | 1.84 Million CAD | 21.69% |
| 2015 FY | 2.42 Million CAD | -33.72% |
| 2015 Q4 | 2.42 Million CAD | 31.39% |
| 2015 Q2 | 1.51 Million CAD | -37.74% |
| 2014 Q4 | 3.66 Million CAD | 1601.53% |
| 2014 Q3 | 215.44 Thousand CAD | 0.0% |
| 2014 Q1 | - CAD | -100.0% |
| 2014 FY | 3.66 Million CAD | 986.74% |
| 2013 FY | 337.33 Thousand CAD | 0.0% |
| 2013 Q4 | 337.33 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| CanadaBis Capital Inc. | 22.96 Million CAD | 95.27% |
| Decibel Cannabis Company Inc. | 142.98 Million CAD | 99.24% |
| Delivra Health Brands Inc. | 10.05 Million CAD | 89.194% |
| Entourage Health Corp. | 31.39 Million CAD | 96.54% |
| Lifeist Wellness Inc. | 13.39 Million CAD | 91.893% |
| Cannara Biotech Inc. | 141.52 Million CAD | 99.232% |
| Medicure Inc. | 28.05 Million CAD | 96.129% |
| PharmaCielo Ltd. | 22.28 Million CAD | 95.127% |
| Rubicon Organics Inc. | 54.89 Million CAD | 98.021% |
| BioSyent Inc. | 41.52 Million CAD | 97.384% |
| Voyageur Pharmaceuticals Ltd. | 2.16 Million CAD | 49.797% |